ALFA Finder| Revenue growth | 56.21% YoY growth in FY26. |
|---|---|
| Margins | EBITDA margin at 16.7% in FY26 vs 20.7% in FY25. |
| Order book | Healthy order book mentioned by MD. |
| Demand visibility | Robust momentum in core export markets: Africa, SE Asia, Latin America. |
| Management confidence | High; confident in profitability improvement as investments yield results. |
Growth
Revenue grew 56.21% YoY to ₹89.6 cr; PAT increased 42.3% YoY to ₹9.67 cr.
Outlook
Focus on 100+ products under registration and scaling CDMO capacity to improve operating leverage.
Risks
Margins impacted by product mix changes, upfront registration costs, and compliance-related expenses.
Earnings Call filed with NSE, NSE: ACCPL. Summary written with AI assistance from the document.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹203.75
- Market cap
- ₹226.5 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 23.4×Sector 43.8×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals Investor Presentation: Key Takeaways
H1 FY27 revenue ₹55.04 Cr (+25.83% YoY), PAT ₹8.20 Cr (+72.63%), EBITDA margin 22.48%. Export share rose to 18.15%.
Accretion Pharmaceuticals Results Update
Accretion Pharmaceuticals reported H1 FY27 net revenue up 25.83% to ₹55.04 crore and PAT up 72.63% to ₹8.20 crore via media release. EBITDA margin improved to 22.48%.
Accretion Pharmaceuticals H1 FY27 Results: Net Profit ₹8.2 Cr, Up 70.8% YoY
Accretion Pharmaceuticals reported unaudited standalone half-year results to 30 September 2026, with revenue of Rs 5,504.10 lakh and profit after tax of Rs 820.14 lakh. The results carry a limited review report from VSSB & Associates.
- Key figure
- Net profit ₹8.2 Cr · +70.8% YoY
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).